Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX)
Levi & Korsinsky, LLP is investigating potential securities law violations involving Tenax Therapeutics (TENX) after its shares dropped 84-85%. This significant decline followed the disclosure that the Phase 3 LEVEL trial of its lead drug, TNX-103, failed to meet both its primary and key …